Plain-English translation of NCT03510208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new imaging agent called that combines a protein-based medicine with a fluorescent dye. The dye is designed to help surgeons see malignant brain tumors during surgery by making cancer cells glow under special light. The trial aims to find the safest dose and best timing for using this medication to maximize how well surgeons can distinguish tumor from healthy brain tissue.
Currently, surgeons sometimes struggle to see exactly where a malignant brain tumor ends and normal brain tissue begins during surgery. This medication could help surgeons remove more of the cancer while avoiding damage to healthy brain areas, potentially improving surgical outcomes.
You likely qualify if…
You likely don't qualify if…
If you are enrolled, you will receive an injection of the fluorescent dye medication 1 to 5 days before your planned brain surgery. Some participants may also receive a preliminary dose of unlabeled medication to improve how well the dye works. During your standard surgical procedure, surgeons will use special imaging equipment to see if the dye helps them identify the tumor. The study team will monitor your safety throughout and collect blood tests and heart rhythm checks as needed.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States